Words of wisdom. Re: overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
Schenk
Ellen A M
EA
Department of Urology, Erasmus MC, Rotterdam, The Netherlands. e.schenk-braat@erasmusmc.nl